FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009310564> ?p ?o ?g. }

• W3009310564 endingPage "280" @default.
• W3009310564 startingPage "274" @default.
• W3009310564 abstract "The purpose of this study was to develop a reproducible preclinical Fusarium solani keratitis model, which would allow comparative testing of currently available antifungals (NATACYN [Alcon, Fort Worth, TX], voriconazole 1%, and amphotericin B 0.1%) as well as efficacy testing of new antifungals for translation into clinical practice in the future.The rabbit F. solani keratitis model was developed in New Zealand white rabbits using local and systemic immunosuppression. Infection was introduced by intrastromal injection of F. solani spores into one of the immunosuppressed rabbit eyes while the contralateral eye was a control. Progress of the infection was assessed by the clinical features, histopathology, and viable fungal counts. In this study, the efficacy of currently available antifungals (NATACYN [Alcon], voriconazole 1%, and amphotericin B 0.1%) was compared. Rabbits were randomly divided (n=4 in each group), and the respective antifungal was instilled topically 5 times/day for 7 days. Treatment effects were analyzed by evaluating the anterior segment with the help of slit-lamp, histopathological findings and viable fungal culture at the end of the experiment.We report the development of a reproducible and progressive rabbit F. solani keratitis model as shown by the substantial viable fungal counts (3 log CFU), the presence of large patchy lesions and substantial hypopyon in the 12-day model correlated with specific histopathological analysis for fungus (extended F. solani hyphae from midcorneal stroma into the anterior chamber and traverse Descemet membrane with anterior chamber suppurative plaque). Voriconazole 1% and NATACYN revealed significant reduction of the fungal wound area (P=0.02 and 0.021), respectively, while amphotericin B 0.1% exhibited P value of 0.083 compared with their infected nontreated controls. Voriconazole 1% and amphotericin B 0.1% showed significant viable fungal count differences (P=0.004 and 0.01), respectively, whereas P value of NATACYN was 0.337 compared with control infected corneas.The reported rabbit fungal keratitis model can be used for screening new antifungals and evaluating currently available antifungals to facilitate better clinical outcomes. Voriconazole 1% showed the best efficacy among the three tested currently available antifungals by showing the significant differences in both wound size and viable fungal count comparisons in our F. solani rabbit keratitis model." @default.
• W3009310564 created "2020-03-13" @default.
• W3009310564 creator A5007551999 @default.
• W3009310564 creator A5015637445 @default.
• W3009310564 creator A5054022611 @default.
• W3009310564 creator A5068849862 @default.
• W3009310564 creator A5075444177 @default.
• W3009310564 creator A5080268156 @default.
• W3009310564 date "2020-03-05" @default.
• W3009310564 modified "2023-10-17" @default.
• W3009310564 title "Rabbit Fungal Keratitis Model of Fusarium solani Tested Against Three Commercially Available Antifungal Drugs" @default.
• W3009310564 cites W1536674483 @default.
• W3009310564 cites W1598646876 @default.
• W3009310564 cites W1857746980 @default.
• W3009310564 cites W1965219674 @default.
• W3009310564 cites W1967363770 @default.
• W3009310564 cites W199741662 @default.
• W3009310564 cites W2004272435 @default.
• W3009310564 cites W2006367958 @default.
• W3009310564 cites W2010533629 @default.
• W3009310564 cites W2012409544 @default.
• W3009310564 cites W2023866233 @default.
• W3009310564 cites W2033766574 @default.
• W3009310564 cites W2035002065 @default.
• W3009310564 cites W2052661353 @default.
• W3009310564 cites W2064185190 @default.
• W3009310564 cites W2092772371 @default.
• W3009310564 cites W2094015492 @default.
• W3009310564 cites W2094123091 @default.
• W3009310564 cites W2103617967 @default.
• W3009310564 cites W2107138744 @default.
• W3009310564 cites W2122104511 @default.
• W3009310564 cites W2149846968 @default.
• W3009310564 cites W2163099413 @default.
• W3009310564 cites W2170740826 @default.
• W3009310564 cites W2180471991 @default.
• W3009310564 cites W2318733194 @default.
• W3009310564 cites W2407547081 @default.
• W3009310564 cites W2483109510 @default.
• W3009310564 cites W2530689043 @default.
• W3009310564 cites W2566869458 @default.
• W3009310564 cites W2725794499 @default.
• W3009310564 cites W2766187621 @default.
• W3009310564 cites W2806191573 @default.
• W3009310564 cites W2883913440 @default.
• W3009310564 cites W2887460592 @default.
• W3009310564 cites W4237275920 @default.
• W3009310564 doi "https://doi.org/10.1097/icl.0000000000000689" @default.
• W3009310564 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7447183" @default.
• W3009310564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32134799" @default.
• W3009310564 hasPublicationYear "2020" @default.
• W3009310564 type Work @default.
• W3009310564 sameAs 3009310564 @default.
• W3009310564 citedByCount "4" @default.
• W3009310564 countsByYear W30093105642021 @default.
• W3009310564 countsByYear W30093105642022 @default.
• W3009310564 countsByYear W30093105642023 @default.
• W3009310564 crossrefType "journal-article" @default.
• W3009310564 hasAuthorship W3009310564A5007551999 @default.
• W3009310564 hasAuthorship W3009310564A5015637445 @default.
• W3009310564 hasAuthorship W3009310564A5054022611 @default.
• W3009310564 hasAuthorship W3009310564A5068849862 @default.
• W3009310564 hasAuthorship W3009310564A5075444177 @default.
• W3009310564 hasAuthorship W3009310564A5080268156 @default.
• W3009310564 hasBestOaLocation W30093105641 @default.
• W3009310564 hasConcept C142724271 @default.
• W3009310564 hasConcept C16005928 @default.
• W3009310564 hasConcept C2776079991 @default.
• W3009310564 hasConcept C2778342517 @default.
• W3009310564 hasConcept C2778560704 @default.
• W3009310564 hasConcept C2779117757 @default.
• W3009310564 hasConcept C2779548794 @default.
• W3009310564 hasConcept C2779629538 @default.
• W3009310564 hasConcept C2780690907 @default.
• W3009310564 hasConcept C2908607901 @default.
• W3009310564 hasConcept C544855455 @default.
• W3009310564 hasConcept C71924100 @default.
• W3009310564 hasConcept C86803240 @default.
• W3009310564 hasConcept C89423630 @default.
• W3009310564 hasConceptScore W3009310564C142724271 @default.
• W3009310564 hasConceptScore W3009310564C16005928 @default.
• W3009310564 hasConceptScore W3009310564C2776079991 @default.
• W3009310564 hasConceptScore W3009310564C2778342517 @default.
• W3009310564 hasConceptScore W3009310564C2778560704 @default.
• W3009310564 hasConceptScore W3009310564C2779117757 @default.
• W3009310564 hasConceptScore W3009310564C2779548794 @default.
• W3009310564 hasConceptScore W3009310564C2779629538 @default.
• W3009310564 hasConceptScore W3009310564C2780690907 @default.
• W3009310564 hasConceptScore W3009310564C2908607901 @default.
• W3009310564 hasConceptScore W3009310564C544855455 @default.
• W3009310564 hasConceptScore W3009310564C71924100 @default.
• W3009310564 hasConceptScore W3009310564C86803240 @default.
• W3009310564 hasConceptScore W3009310564C89423630 @default.
• W3009310564 hasIssue "5" @default.
• W3009310564 hasLocation W30093105641 @default.
• W3009310564 hasLocation W30093105642 @default.
• W3009310564 hasLocation W30093105643 @default.
• W3009310564 hasLocation W30093105644 @default.

• next